The correlation of Epstein-Barr virus expression and lymphocyte subsets with the clinical presentation of nodular sclerosing Hodgkin disease

Abstract We describe a case of primary Hodgkin disease of the terminal ileum in a 38-year-old man with Crohn disease of 24 years' duration. The infiltrate was located in an ulcerated fistula involving the terminal ileum and urinary bladder. Reed-Sternberg cells and their variants were characteristically positive for CD15, fascin, and CD30 and showed focal positivity for CD20. Epstein-Barr virus messenger RNA was also detected in the neoplastic cells. Staging revealed no evidence of other lymph node or organ involvement. Although rare, primary gastrointestinal Hodgkin disease arising in the setting of Crohn disease may have a stronger association with Epstein-Barr virus infection than conventional Hodgkin disease.

Download Full-text

Viral Hepatitis: Retrospective Review in a Canadian Pediatric Hospital

ISRN Pediatrics ◽

10.5402/2011/182964 ◽

2011 ◽

Vol 2011 ◽

pp. 1-4 ◽

Cited By ~ 2

Author(s):

Paulina Cybulska ◽

Andy Ni ◽

Carolina Jimenez-Rivera

Keyword(s):

Viral Hepatitis ◽

Epstein Barr Virus ◽

Hepatitis A ◽

Chart Review ◽

Clinical Presentation ◽

Retrospective Chart Review ◽

Barr Virus ◽

Mild Abdominal Pain ◽

Epstein Barr ◽

Acute And Chronic Hepatitis

Introduction. Clinical presentation of viral hepatitis ranges from mild symptoms to fulminant hepatitis. Our aim is to describe clinical presentation and outcomes of children with viral hepatitis from the Eastern Ontario/Western Quebec regions of Canada. Methods. Retrospective chart review of children diagnosed with viral hepatitis at our institution from January 1, 1998, to December 31, 2007. Results. There were 261 charts reviewed, only 64 had a confirmed viral etiology: 34 (53%) hepatitis B (HBV), 16 (25%) hepatitis C (HCV), 4 (6.3%) hepatitis A (HAV), 7 (11%) cytomegalovirus (CMV), and 3 (4.7%) Epstein-Barr virus (EBV). Children with HBV presented at a mean age of 6.4±4.6 years. Spontaneous seroconversion (appearance of HBVeAb and loss of HBVeAg) occurred in 21/34 (61.7%). Children with acute hepatitis (HAV, CMV, and EBV) presented with mild abdominal pain, jaundice, and fevers. Overall outcome was excellent. Conclusion. Acute and chronic hepatitis in children has a benign course; moreover, HBV spontaneous seroconversion is common in pediatric patients.

Download Full-text

The effect of Epstein – Barr Virus Viremia on the Progression to Severe COVID-19

10.21203/rs.3.rs-432640/v1 ◽

2021 ◽

Author(s):

Jae Hyoung Im ◽

Chung Hyun Nahm ◽

Young Soo Je ◽

Jin-Soo Lee ◽

Hea Yoon Kwon ◽

...

Keyword(s):

Epstein Barr Virus ◽

Lymphocyte Subsets ◽

Severe Pneumonia ◽

Simplified Acute Physiology Score ◽

Negative Group ◽

Barr Virus ◽

Saps Ii ◽

High Incidence ◽

Epstein Barr ◽

Ebv Viremia

Abstract BackgroundCoronavirus disease 2019 (COVID-19) can reactivate several latent viruses. Epstein–Barr virus (EBV) is a latent virus that is frequently reactivated in patients with critical illnesses. Recently, a high incidence of viremia has been reported in patients with severe COVID-19. However, it is unclear whether EBV viremia is the result of the severity of COVID-19 or if it affects the severity of COVID-19. Therefore, we conducted a cohort study to evaluate the effects of EBV on the progression of COVID-19.MethodsWe compared the incidence of EBV viremia between the COVID-19 and non-COVID-19 groups. Simplified Acute Physiology Score (SAPS) II and lymphocyte subsets were analyzed in patients with COVID-19. We also observed that patients with COVID-19 with EBV viremia progressed to severe pneumonia more often than those without EBV viremia.ResultsTwo hundred and nine patients with COVID-19 were compared with the control (non-COVID-19) group. The incidence of EBV viremia was lower in the COVID-19 group than in the non-COVID-19 group (17.1% vs. 26.8%, P=0.034). In the subgroup analysis of the COVID-19 group, the EBV-positive group patients had more severe COVID-19 infection than the EBV-negative group (SAPS II, 22.3 vs. 17.4%; P=0.002). However, progression to moderate or severe pneumonia in patients with mild COVID-19 was rather high in the EBV-negative group (not statistically significant), contrary to our expectations.ConclusionsAlthough the severity of COVID-19 may affect EBV viremia, there is no evidence that EBV viremia is a factor that exacerbates pneumonia in patients with early COVID-19. The effect of EBV viremia on prolonged organizing pneumonia should be further studied.

Download Full-text